Clinical trials: High-risk Medications
Altitude, Ultraviolet Rays
Ultraviolet Exposure, Antioxidant Use and Skin Erythema at Extreme High Altitude
With the increasing tourism and adventure travel into extreme environments comes the need to reassess the required protection against ultraviolet (UV) radiation and possible other oxidative stresses.
- Conditions
- Altitude, Ultraviolet Rays, Antioxidants, Oxidative Stress
- Trial name
- NCT00685438
- Where
- Nepal
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Medication-related Osteonecrosis of the Jaw
Autologous Platelet Concentrates on the Healing of Extraction Sockets
This study will evaluate the effect of A-PRF, a second-generation APC, on early wound healing in high-risk MRONJ patients following dental extractions, utilising advanced non-invasive methods to assess and associate molecular and…
- Trial name
- NCT07673848
- Testing
- Application of A-PRF into extraction socket
- Volunteers
- 44 people
- Sponsor
- Queen Mary University of London
Prediabetic State
Effects of TCM on Beta-cell Function and Insulin Resistance in High Risk Chinese Individuals for T2D (TCM_PDiab_P01)
This study involves prediabetes volunteers who are at high risk of developing diabetes, including those with family history of diabetes, metabolic syndrome, fatty liver, polycystic ovary syndrome and history of gestational…
- Trial name
- NCT04441216
- Testing
- Rhizoma Coptidis, Radix Astragali and Flos Lonicerae, Rhizoma Coptidis, Radix Astragali and Flos Lonicerae, Ophiopogonis Radix
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Hypotension Drug-Induced, Spinal Aneshtesia
Effect of Lateral Decubitus Position After Spinal Anesthesia on Hemodynamic Stability in High-Risk Geriatric Patients
Spinal anesthesia is a common and preferred anesthetic technique for lower extremity orthopedic surgery in elderly patients. However, it can cause a significant drop in blood pressure (hypotension), especially in high-risk older…
- Conditions
- Hypotension Drug-Induced, Spinal Aneshtesia, Geriatric, Orthopedic Surgery Patients
- Trial name
- NCT07597148
- Testing
- Lateral Decubitus Positioning, Immediate Supine Positioning
- Volunteers
- 70 people
- Sponsor
- University of Health Sciences Balikesir Hospital Eduation and Research
Opioid-Related Disorders, Opiate Addiction
Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain
The purpose of this study is to evaluate the effect on pain intensity (PI) of structured discontinuation of long-term opioid analgesic therapy compared to continuation of opioid therapy in Suboptimal and Optimal Responders to…
- Conditions
- Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02741076
- Testing
- Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER), Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
- Where
- 61 sites in United States
- Volunteers
- 44 people
- Sponsor
- Member Companies of the Opioid PMR Consortium
Coronary Heart Disease, Acute Coronary Syndrome
A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography
BioFreedom™ is the world's first polymer-free drug-coated stent (DCS), utilizing a proprietary microstructured surface technology.
- Trial name
- NCT07230847
- Testing
- BioFreedom™, Xience
- Where
- China
- Volunteers
- 60 people
- Sponsor
- China National Center for Cardiovascular Diseases
Coronary Artery Disease (CAD)
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
To determine the efficacy of prasugrel versus clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting…
- Trial name
- TRIGGER-PCI (NCT00910299)
- Testing
- Prasugrel, Clopidogrel
- Where
- 27 sites in United States, Germany
- Volunteers
- 423 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease
SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3
This study is a prospective, open-label, two-arm, randomized multicenter trial to compare the efficacy and safety of clopidogrel versus aspirin monotherapy beyond the standard duration of dual antiplatelet therapy (DAPT) (more…
- Trial name
- SMART-CHOICE3 (NCT04418479)
- Testing
- Aspirin, Clopidogrel
- Where
- South Korea
- Volunteers
- 5,506 people
- Sponsor
- Joo-Yong Hahn
Bone Marrow Suppression, Brain and Central Nervous System Tumors
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00005796
- Testing
- filgrastim, gene therapy, lomustine
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
This phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual combination of drugs used for treatment.
- Conditions
- Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT03984448
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 634 sites in United States
- Volunteers
- 363 people
- Sponsor
- National Cancer Institute (NCI)
Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR)
Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
Patients with acute coronary syndrome (ACS) who have both high ischemic risk and high bleeding risk represent a challenging population following percutaneous coronary intervention (PCI), as prolonged dual antiplatelet therapy…
- Conditions
- Acute Coronary Syndrome (ACS), High Bleeding Risk(HBR), Coronary Artery Disease (CAD)
- Trial name
- NCT07374718
- Testing
- IVUS-guided BioFreedomTM Drug-Coated Stent Implantation + 1-Month DAPT Followed by 11-Month P2Y12 Inhibitor Monotherapy, Angiography-guided Conventional Drug-Eluting Stent Implantation + 12-Month Dual Antiplatelet Therapy (Aspirin + P2Y12 Inhibitor)
- Where
- China
- Volunteers
- 468 people
- Sponsor
- Shenyang Northern Hospital
Physical Activity, Life Style
Cardiovascular Disease Prevention Strategies for High-risk Urban Sedentary Employees in Karachi, Pakistan
Heart diseases and other non-communicable diseases are serious health issues in countries like Pakistan. Many people who work in offices, like bank employees, sit for more than 8 hours a day.
- Conditions
- Physical Activity, Life Style, Dietary Habits, Cardiovascular Diseases
- Trial name
- m-LIfE (NCT06981247)
- Testing
- m-LIfE: mobile based lifestyle intervention for employees to increase their physical activity and promote healthy diet., Routine care arm
- Where
- Pakistan
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
SCLC, Malignant Melanoma
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA…
- Conditions
- SCLC, Malignant Melanoma, Sarcoma, High Risk Neuroblastoma
- Trial name
- NCT05130255
- Testing
- GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Y-mAbs Therapeutics
Knowledge, Practice Nurse's Scope
Managing High-alert Medication Administration and Errors
High-alert medications are drugs that may lead to serious harm when they are wrongly administered to patients. Safe medication administration is the crucial role of nursing staff.
- Conditions
- Knowledge, Practice Nurse's Scope, Competence, Nurse's Role
- Trial name
- NCT06366607
- Testing
- high-alert medication administration
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Matrouh University
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
- Trial name
- NCT00003407
- Testing
- amifostine trihydrate, cytarabine, mitoxantrone hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Rush University Medical Center
Coronary Artery Disease
A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction
Despite the relative safety of PCI with new generation stents, peri-PCI thrombotic complications, including myocardial infarction and myocardial injury, are common in elective PCI, occurring in up to 30% of patients.
- Trial name
- NCT05332262
- Testing
- Assessment of platelet reactivity, Troponin measurement
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Florida
Acute Leukemia
An Observational Analysis of Voriconazole Therapeutic Drug Concentration Monitoring, Pharmacogenomics and Clinical Outcome Correlations in High-risk Hematology Patients
Hematology patients are at high risk for invasive fungal infection (IFI) and are being treated with voriconazole (VOR) at Princess Margaret Hospital (PMH).
- Trial name
- NCT01321372
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- University Health Network, Toronto
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 66 sites in United States, China and 1 more
- Volunteers
- 952 people
- Sponsor
- Genmab
High Cholesterol, Diabetes
Complete Lifestyle Medicine Intervention Program
This project will use a mixed design and will be conducted at the West Parry Sound Health Centre. Based on similar studies there is an expected 10% drop-out rate so 20 participants per group will be invited to aim to have 15…
- Conditions
- High Cholesterol, Diabetes, Obesity, Hypertension
- Trial name
- CLIP (NCT06192251)
- Testing
- Lifestyle Medicine
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Northern Ontario School of Medicine
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
The purpose of this study is to evaluate the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in participants with HR-MDS or CMML, or low-blast AML.
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
- Trial name
- NCT02610777
- Testing
- Azacitidine, Pevonedistat
- Where
- 59 sites in United States, Belgium and 10 more
- Volunteers
- 120 people
- Sponsor
- Millennium Pharmaceuticals, Inc.